![]() The study was conducted between August 2015 and May 2016 Yes (double blind - neither medical staff, nor participants knew which treatment participants were taking) European Psychosocial Special Interest Groupīack to Studies Overview Clinical trials identifierĪ Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-CFTR Mutation and With a Second CFTR Mutation That Is Not Likely to Respond to VX-661 and/or Ivacaftor Therapy (F508del/NR)Īged 12 Years and Older, Heterozygous for the F508del-CFTR Mutation and With a Second CFTR Mutation That Is Not Likely to Respond to VX-661 and/or Ivacaftor Therapy (F508del/NR).European Cystic Fibrosis Nutrition Group.Cystic Fibrosis Molecular & Cell Biology and Physiology Basic Science.ECFS Non Tuberculous Mycobacteria Working Group.Complete CFTR gene mutation analysis in European patients with Cystic Fibrosis.CFQ-R questionnaire and CF candidates for lung transplant.ECFS / CF Europe Post-Doctoral Research Fellowship. ![]() ![]() Cystic Fibrosis Molecular and Cell Biology and Physiology Basic Science.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |